<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">313</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2009-0-3-4-43-48</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. NEW TECHNOLOGIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. НОВЫЕ ТЕХНОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">MEMBRANE LEc EXPRESSION IN BREAST CANCER CELLS</article-title><trans-title-group xml:lang="ru"><trans-title>МЕМБРАННАЯ ЭКСПРЕССИЯ LEc НА КЛЕТКАХ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Udalova</surname><given-names>Ya. A.</given-names></name><name xml:lang="ru"><surname>Удалова</surname><given-names>Я. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>yanadoc@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bovin</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Бовин</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Obukhova</surname><given-names>P. S.</given-names></name><name xml:lang="ru"><surname>Обухова</surname><given-names>П. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shilova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Шилова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kovrigina</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Ковригина</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Subbotina</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Субботина</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Timoshenko</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Тимошенко</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Galanina</surname><given-names>O. E.</given-names></name><name xml:lang="ru"><surname>Галанина</surname><given-names>О. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kadagidze</surname><given-names>Z. G.</given-names></name><name xml:lang="ru"><surname>Кадагидзе</surname><given-names>З. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Letyagin</surname><given-names>V. P.</given-names></name><name xml:lang="ru"><surname>Летягин</surname><given-names>В. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tupitsyn</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Тупицын</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru">ГУ РОНЦ им. Н.Н. Блохина РАМН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">M.M. Shemyakin &amp; Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">Институт биоорганической химии им. М.М. Шемякина и Ю.А. Овчинникова РАН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2009-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2009</year></pub-date><issue>3-4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>48</lpage><history><date date-type="received" iso-8601-date="2014-09-10"><day>10</day><month>09</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-09-10"><day>10</day><month>09</month><year>2014</year></date></history><permissions><copyright-year>2009</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/313">https://ojrs.abvpress.ru/ojrs/article/view/313</self-uri><abstract xml:lang="en"><p>Affine chromatography was used to isolate Lec antibodies from the sera of a healthy female donor with the high titers of these anti- bodies, which were labeled with biotin. The study enrolled 51 patients with primary breast cancer (BC). Antigen expression was found by immunohistochemistry and flow cytometry. With these two techniques being used, the detection rate of Lec expression in BC cells was 65% (33/51); the antigen was most frequently found by flow cytometry as compared with immunohistochemistry: 72 and 58% of cases, respectively.</p></abstract><trans-abstract xml:lang="ru"><p>Из сыворотки крови здоровой женщины-донора с высокими титрами антител к Lec эти антитела были выделены методом аффинной хроматографии и помечены биотином. В исследование включена 51 больная первичным раком молочной железы (РМЖ). Выявление экспрессии антигена проводили методами иммуногистохимии и проточной цитометрии. При использовании двух этих методов частота обнаружения экспрессии Lec на клетках РМЖ составила 65% (33 случая из 51), наиболее часто антиген выявлялся с помощью метода проточной цитометрии по сравнению с иммуногистохимией: 72 и 58% наблюдений соответственно.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>membrane expression</kwd><kwd>antibodies</kwd><kwd>Lec</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>мембранная экспрессия</kwd><kwd>антитела</kwd><kwd>Lec.</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Vollmers H.P., Brandlein S. Nature’s best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Hum Antibodies 2002;11(2):131—42.</mixed-citation><mixed-citation xml:lang="ru">Vollmers H.P., Brandlein S. Nature’s best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Hum Antibodies 2002;11(2):131—42.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Brandlein S., Vollmers H.P. Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 2004;19(3):897—905.</mixed-citation><mixed-citation xml:lang="ru">Brandlein S., Vollmers H.P. Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 2004;19(3):897—905.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Vollmers H.P., Brandlein S. Natural IgM antibodies: from parias to parvenus. Histol Histopathol 2006;21(12):1355—66.</mixed-citation><mixed-citation xml:lang="ru">Vollmers H.P., Brandlein S. Natural IgM antibodies: from parias to parvenus. Histol Histopathol 2006;21(12):1355—66.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Vollmers H.P., Brandlein S. Natural IgM antibodies: the orphaned molecules in immune surveillance. Histol Histopathol 2006;58(5—6):755—65.</mixed-citation><mixed-citation xml:lang="ru">Vollmers H.P., Brandlein S. Natural IgM antibodies: the orphaned molecules in immune surveillance. Histol Histopathol 2006;58(5—6):755—65.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Bohn J. Are natural antibodies involved in tumour defence. Immunol Let 1999;69(3):317—20.</mixed-citation><mixed-citation xml:lang="ru">Bohn J. Are natural antibodies involved in tumour defence. Immunol Let 1999;69(3):317—20.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000;37(18):1141—9.</mixed-citation><mixed-citation xml:lang="ru">Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000;37(18):1141—9.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Kasaian M.T., Casali P. Autoimmunity-prone (CD5 B) cells, nat- ural antibodies and self-recognition. Autoimmunity 1993;15(4):315—29.</mixed-citation><mixed-citation xml:lang="ru">Kasaian M.T., Casali P. Autoimmunity-prone (CD5 B) cells, nat- ural antibodies and self-recognition. Autoimmunity 1993;15(4):315—29.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Bofill M., Janossy G., Janossa M. et al. Human B-cell development. II. Subpopulations in human fetus. J Immunol 1985;134(3):1531—8.</mixed-citation><mixed-citation xml:lang="ru">Bofill M., Janossy G., Janossa M. et al. Human B-cell development. II. Subpopulations in human fetus. J Immunol 1985;134(3):1531—8.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Brandlein S., Pohle T., Ruoff N. et al. Natural IgM antibodies and immunosur- veillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003;63:7995—8005.</mixed-citation><mixed-citation xml:lang="ru">Brandlein S., Pohle T., Ruoff N. et al. Natural IgM antibodies and immunosur- veillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003;63:7995—8005.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Pohle T., Brandlein S., Ruoff N. et al. Lipoptosis: a tumor-specific cell death by antibody-induced intracellular lipid accu- mulation. Cancer Res 2004;64:3900—6.</mixed-citation><mixed-citation xml:lang="ru">Pohle T., Brandlein S., Ruoff N. et al. Lipoptosis: a tumor-specific cell death by antibody-induced intracellular lipid accu- mulation. Cancer Res 2004;64:3900—6.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Rye P.D., Walker R.A. Prognostic value of breast cancer-associated glyco- protein detected by monoclonal antibody Lu-BCRU-G7. Eur J Cancer 1994;30(7):1007—12.</mixed-citation><mixed-citation xml:lang="ru">Rye P.D., Walker R.A. Prognostic value of breast cancer-associated glyco- protein detected by monoclonal antibody Lu-BCRU-G7. Eur J Cancer 1994;30(7):1007—12.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Rye P.D., Bovin N.V., Vlasova E.V., Walker R.A. Monoclonal antibody LU- BCRU-G7 against a breast tumor-associ- ated glycoprotein recognizes the disac- charide Gal beta1-3GlcNAc. Glycobiology 1995;5(4):385—9.</mixed-citation><mixed-citation xml:lang="ru">Rye P.D., Bovin N.V., Vlasova E.V., Walker R.A. Monoclonal antibody LU- BCRU-G7 against a breast tumor-associ- ated glycoprotein recognizes the disac- charide Gal beta1-3GlcNAc. Glycobiology 1995;5(4):385—9.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Тупицын Н.Н., Летягин В.П., П ниченко А.В. и др. Новые иммунологические маркеры (CD71, LU-BCRU- G7), взаимосвязанные с прогнозом рака молочной железы. Совр онкол 2001;3(4):161—3.</mixed-citation><mixed-citation xml:lang="ru">Тупицын Н.Н., Летягин В.П., П ниченко А.В. и др. Новые иммунологические маркеры (CD71, LU-BCRU- G7), взаимосвязанные с прогнозом рака молочной железы. Совр онкол 2001;3(4):161—3.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Тупицын Н.Н., Галанина О.Е., Бовин Н.В. и др. Уровень специфических антител к углеводному антигену Lec понижен у больных раком молочной железы. Иммунология 2008;(2):31—3.</mixed-citation><mixed-citation xml:lang="ru">Тупицын Н.Н., Галанина О.Е., Бовин Н.В. и др. Уровень специфических антител к углеводному антигену Lec понижен у больных раком молочной железы. Иммунология 2008;(2):31—3.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Tupitsyn N.N., Kadagidze Z.G., Tuichiev I.K. et al. Relationship between semiquantitative and quantitative parameters of local immune response in gastric cancer. Exper oncol 1995;17:31—6.</mixed-citation><mixed-citation xml:lang="ru">Tupitsyn N.N., Kadagidze Z.G., Tuichiev I.K. et al. Relationship between semiquantitative and quantitative parameters of local immune response in gastric cancer. Exper oncol 1995;17:31—6.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Rye P.D., Bovin N.V. Selection of carbohydrate-binding cell phenotypes using oligosaccharide-coated magnetic particles. Glycobiology 1997;7(2):179—82.</mixed-citation><mixed-citation xml:lang="ru">Rye P.D., Bovin N.V. Selection of carbohydrate-binding cell phenotypes using oligosaccharide-coated magnetic particles. Glycobiology 1997;7(2):179—82.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Vollmers H.P., Zimmerman U., Krenn U. et al. Adjuvant therapy for gas- tric adenocarcinoma with apoptosis- inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 1998;5:549—52.</mixed-citation><mixed-citation xml:lang="ru">Vollmers H.P., Zimmerman U., Krenn U. et al. Adjuvant therapy for gas- tric adenocarcinoma with apoptosis- inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 1998;5:549—52.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Beutner U., Lorenz U., Illert B. et al. Neoadjuvant therapy of gastric cancer with human monoclonal IgM antibody SC-1: impact on immune system. Oncol Rep 2008;19:761—9.</mixed-citation><mixed-citation xml:lang="ru">Beutner U., Lorenz U., Illert B. et al. Neoadjuvant therapy of gastric cancer with human monoclonal IgM antibody SC-1: impact on immune system. Oncol Rep 2008;19:761—9.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Illert B., Otto C., Vollmers H.P. et al. Human antibody SC-1 reduces dissemi- nated tumor cells in nude mice with human gastric cancer. Oncol Rep 2005;13(4):765—70.</mixed-citation><mixed-citation xml:lang="ru">Illert B., Otto C., Vollmers H.P. et al. Human antibody SC-1 reduces dissemi- nated tumor cells in nude mice with human gastric cancer. Oncol Rep 2005;13(4):765—70.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Крохина О.В., Летягин В.П., Тупицын Н.Н. и др. Иммуноцитологическая диагностика микрометастазов рака молочной железы в костный мозг. Иммунол гемопоэз 2007—2008;5—6:116—31.</mixed-citation><mixed-citation xml:lang="ru">Крохина О.В., Летягин В.П., Тупицын Н.Н. и др. Иммуноцитологическая диагностика микрометастазов рака молочной железы в костный мозг. Иммунол гемопоэз 2007—2008;5—6:116—31.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
